Skip to main content

Table 4 EULAR response, low disease activity and remission rates during TNF inhibitor treatment of the rheumatoid arthritis cohort

From: Comparison of remission criteria in a tumour necrosis factor inhibitor treated rheumatoid arthritis longitudinal cohort: patient global health is a confounder

 

3 months

6 months

12 months

Good response (%)

39.5

45.8

50.5

Moderate response (%)

49.5

39.8

31.9

Nonresponse (%)

14

14.4

17.6

DAS28(4v)-CRP <3.2 (%)

42.3

50.9

54.9

Low disease activity (%)

18.5

20.5

17.6

DAS28 remission

53 (23.9%)

65 (30.1%)

102 (37.4%)

Boolean remission

7 (3.2%)

23 (10.6%)

27 (9.9%)

  1. EULAR, European League Against Rheumatism, TNF, tumour necrosis factor; DAS28(4v)-CRP, disease activity score based on joints using four variables and including C-reactive protein as the inflammatory marker; DAS28, disease activity score based on 28 joints.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us